



Australian Government

Department of Health

Office of the Gene Technology Regulator

08 February 2021

AstraZeneca Pty Ltd granted licence for the commercial supply of a COVID-19 vaccine

The Office of the Gene Technology Regulator (OGTR) has issued licence DIR 180 to AstraZeneca Pty Ltd. This licence allows for the importation, transport, storage and disposal of a COVID-19 vaccine.

Approval from the Therapeutic Goods Administration (TGA) is also required for the commercial supply and administration of the vaccine as part of the government's COVID-19 Vaccine and Treatment Strategy.

The licence decision was informed by a Risk Assessment and Risk Management Plan (RARMP) undertaken by the OGTR with input from stakeholders nationwide. This included consultation with the public, state and territory governments, Australian Government agencies, the Minister for the Environment, and the Gene Technology Technical Advisory Committee.

Submissions are summarised in Appendix B and C of the RARMP, together with information about how the issues raised relating to health, safety and the environment were considered.

The RARMP concludes that import, transport, storage and disposal of the AstraZeneca COVID-19 vaccine poses negligible risks to people and the environment.

General licence conditions have been imposed to ensure ongoing oversight of the supply and distribution of the vaccine.

The finalised RARMP, a summary of the RARMP, the licence, and questions and answers can be seen on the [DIR 180](#) page of OGTR website. You can also request them via the contacts detailed below.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601
Tel: 1800 181 030 E-mail: ogtr@health.gov.au
[OGTR website](#)